Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the safety of MDV3100 given in combination with Docetaxel in men with advanced prostate cancer.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
Collaborators
NCT06594926 · Prostate Cancer
NCT06926283 · Prostate Cancer, Other Solid Tumors, and more
NCT07177937 · Small Cell Lung Cancer, Melanoma, and more
NCT06844383 · Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
NCT06487507 · Prostate Cancer
Memorial Sloan Kettering Cancer Center
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Virginia Oncology Associates
Norfolk, Virginia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions